Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2013)	10/13/2008 10:22:39 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CPHD is up 14.73% with better volume.<g> bigcharts.marketwatch.com It announced on Oct 7 the release of Xpert(TM) vanA/vanB as a European CE IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test delivers rapid detection of vanA and/or vanB genes, which are the genes most commonly associated with vancomycin-resistant enterococci.(The 45-minute test runs on CPHD's GeneXpert® System, and is the first test developed and manufactured by CPHD inn Bromma, Sweden. This rapid test offers an obvious advantage over conventional tests that require microbial growth on selective media & seems important in the combat of these nosocomial infections. Bernard